pd 131628 has been researched along with Bacterial Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Finegold, SM; Molitoris, E; Reeves, D; Wexler, HM | 1 |
| Allen, SD; Barry, AL; Fuchs, PC; Gerlach, EH; Pfaller, MA | 1 |
2 other study(ies) available for pd 131628 and Bacterial Disease
| Article | Year |
|---|---|
In-vitro activity of clinafloxacin (CI-960) and PD 131628-2 against anaerobic bacteria.
Topics: Anti-Infective Agents; Bacteria, Anaerobic; Bacterial Infections; Culture Media; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Naphthyridines; Quinolones | 1994 |
Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates.
Topics: Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Naphthyridines | 1991 |